An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer
  • CME

Watch this CME-certified on-demand Webcast of a CCO symposium at ASCO 2019 to get up to date on how experts are managing patients with HR+/HER2- MBC, including the optimal application of CDK4/6 inhibitors, the evolving role of PI3K pathway blockade, promising strategies on the horizon for managing resistance, and panel case discussions.
Joyce O'Shaughnessy, MD
Program Director
Adam M. Brufsky, MD, PhD
Sara Hurvitz, MD, FACP
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: July 5, 2019 Expiration: July 4, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate current guidelines and current/emerging clinical trial data on everolimus, palbociclib, ribociclib, and abemaciclib (in addition to others under clinical investigation) to aid in the refinement of current treatment algorithms for patients with de novo or recurrent HR-positive/HER2-negative MBC
  • Describe current therapeutic strategies and ongoing clinical trials of targeted therapy–based combinations for both early-stage and HR-positive, HER2-negative MBC
  • Identify ongoing trials investigating novel treatment options after disease progression on endocrine and/or CDK4/6 inhibitor–based therapy to aid in clinical trial participation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received consulting fees from AbbVie, Agendia, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Ondonate, Pfizer, Puma, Roche, Seattle Genetics, and Syndax.

Faculty

Adam M. Brufsky, MD, PhD

Professor of Medicine
Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Adam M. Brufsky, MD, PhD, has disclosed that he has received consulting fees from Celgene, Lilly, Novartis, Pfizer, Puma, and Roche.
Sara Hurvitz, MD, FACP

Associate Professor of Medicine
Director,
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, Bayer, Biomarin, Boehringer Ingelheim, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Roche, and Seattle Genetics.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other allied healthcare professionals caring for patients with metastatic breast cancer receiving targeted therapy.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians caring for their patients with MBC receiving CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, and promising investigational agents.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 05, 2019, through July 04, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides with key data from the 2019 ESMO Congress created by Clinical Care Options.

Axel Grothey Headshot Axel Grothey, MD Sara Hurvitz, MD, FACP Bradley J. Monk, MD, FACS, FACOG Sandip P. Patel, MD Released: October 10, 2019

Get a preview of key expert selected studies at ESMO 2019 in breast, gastrointestinal, gynecologic, and thoracic malignancies from Clinical Care Options

Axel Grothey Headshot Axel Grothey, MD Sara Hurvitz, MD, FACP Bradley J. Monk, MD, FACS, FACOG Sandip P. Patel, MD Released: September 26, 2019

Review key data on early breast cancer, metastatic breast cancer, and TNBC from ASCO 2019 with Sara Hurvitz, MD, and Joyce O’Shaughnessy, MD

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 14, 2019 Expiration: August 13, 2020

Drs. Todd M. Bauer, Giuseppe Giaccone, Axel Grothey, John L. Marshall, and Michael J. Pishvaian discuss the latest data on 10 key clinical biomarkers in solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Giuseppe Giaccone, MD, PhD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 11, 2019 Expiration: July 10, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?